title: Clinical trials update from European Society of Cardiology meeting 2008: TIME-CHF, BACH, BEAUTIFUL, GISSI-HF, and HOME-HF.
abstract: This article provides information and a commentary on trials relevant to the pathophysiology, prevention and treatment of heart failure presented at the European Society of Cardiology meeting which was held in Munich, Germany from 30th August to 3rd September 2008. Unpublished reports should be considered as preliminary, as analyses may change in the final publication. The TIME-CHF study failed to show that BNP guided therapy was superior to usual care in patients with heart failure. The BACH study suggested that a new biomarker, MR-proANP, was as good as BNP for the diagnosis of heart failure in patients presenting with breathlessness. Ivabradine failed to reduce the incidence of cardiovascular events in patients with coronary artery disease and left ventricular systolic dysfunction in the BEAUTIFUL study, but patients with higher heart rates might have benefited. In GISSI-HF, n-3 PUFA reduced mortality and cardiovascular hospitalisation by a small amount compared to placebo in patients with chronic heart failure, but rosuvastatin had no effect on clinical outcomes. In the HOME-HF study, telemonitoring support failed to reduce the time to first re-hospitalisation or death, or days alive and out of hospital, compared with usual care.
authors.affiliation: Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, Kingston-upon-Hull, HU16 5JQ, UK. a.p.coletta@hull.ac.uk
authors.forename: Alison P
authors.initials: AP
authors.lastname: Coletta
authors.forename: Damien
authors.initials: D
authors.lastname: Cullington
authors.forename: Andrew L
authors.initials: AL
authors.lastname: Clark
authors.forename: John G F
authors.initials: JG
authors.lastname: Cleland
mesh_terms: D001552:Benzazepines / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D002309:Cardiology; D005060:Europe; D005231:Fatty Acids, Unsaturated / Q000097:blood; D005464:Fluorobenzenes / Q000627:therapeutic use; D006333:Heart Failure / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000077550:Ivabradine; D020097:Natriuretic Peptide, Brain / Q000097:blood; D011743:Pyrimidines / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D000068718:Rosuvastatin Calcium; D012955:Societies, Medical; D013449:Sulfonamides / Q000627:therapeutic use
chemical_list: D001552:Benzazepines; D015415:Biomarkers; D005231:Fatty Acids, Unsaturated; D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D020097:Natriuretic Peptide, Brain; D000077550:Ivabradine; D000068718:Rosuvastatin Calcium